| PMC full text: | Published online 2020 Jun 24. doi: 10.1001/jamanetworkopen.2020.13136
|
Table 1.
| Characteristic | No. (%) | Difference (95% CI)a | |
|---|---|---|---|
Control group (n =50) | Colchicine group (n=55) | ||
| Men | 30 (60.0) | 31 (56.4) | 4 (–15 to 23) |
| Age, y, median (IQR) | 65 (54 to 80) | 63 (55 to 70) | 1.5 (–5 to 8) |
| BMI, median (IQR) | 27.7 (24.6 to 30.5) | 27.3 (25.2 to 30.5) | 0.15 (–1.5 to 1.8) |
| Time from admission to enrollment, median (IQR), d | 5 (1 to 8) | 3 (0 to 6) | 0.5 (–1 to 2) |
| Clinical status score | |||
| 3 | 17 (34.0) | 19 (34.5) | 0 (–18 to 18) |
| 4 | 30 (60.0) | 36 (65.5) | –6 (–25 to 13) |
| 5 | 3 (6.0) | 0 | 6 (–1 to 13) |
| Lower respiratory tract infection | 47 (94.0) | 54 (98.2) | –4 (–12 to 4) |
| Persistent cough | 35 (70.0) | 34 (61.8) | 8 (–10 to 26) |
| Anosmia or ageusia | 7 (14.0) | 7 (12.7) | 1 (–12 to 14) |
| Persistent pharyngeal pain | 12 (24.0) | 11 (20.0) | 4 (–12 to 20) |
| Fatigue | 46 (92.0) | 46 (83.6) | 8 (–4 to 20) |
| Pao2 <95 mm Hg | 33 (66.0) | 41 (74.5) | –9 (–26 to 8) |
| Not smoking | 26 (52.0) | 31 (56.3) | –4 (–23 to 15) |
| Formerly smoked | 15 (30.0) | 15 (27.2) | 3 (–14 to 20) |
| Currently smoking | 2 (4.0) | 4 (7.3) | –3 (–12 to 6) |
| Arterial hypertension | 25 (50.0) | 22 (40.0) | 10 (–9 to 29) |
| Diabetes | 12 (24.0) | 9 (16.4) | 8 (–7 to 23) |
| Dyslipidemia | 16 (32.0) | 17 (30.9) | 1 (–17 to 19) |
| Coronary artery disease | 5 (10.0) | 9 (16.4) | –6 (–19 to 7) |
| Valvulopathy | 1 (2.0) | 4 (7.3) | –5 (–13 to 3) |
| Atrial fibrillation | 5 (10.0) | 6 (10.9) | –1 (–13 to 11) |
| Chronic obstructive pulmonary disease | 2 (4.0) | 3 (5.5) | –2 (–10 to 6) |
| Known immunosuppression | 1 (2.0) | 3 (5.5) | –3.5 (–11 to 4) |
| Concomitant COVID-19 treatmentb | |||
| Chloroquine or hydroxychloroquine | 48 (96.0) | 55 (100) | –4 (–9 to 1) |
| Azithromycin | 46 (92.0) | 51 (92.7) | –1 (–11 to 9) |
| Lopinavir or ritonavir | 19 (38.0) | 14 (25.5) | –13 (–5 tο 31) |
| Tocilizumab | 2 (4.0) | 2 (3.6) | 0 (–8 to 8) |
| Concomitant anticoagulation medication | 26 (52.0) | 31 (56.3) | –4 (–23 to 15) |
| Temperature, median (IQR), °C | 37.7 (37.5 to 38.1) | 37.7 (37.5 to 38.1) | 0 (–0.1 to 0.1) |
| Pao2, median (IQR), mm Hg | 80 (73 to 93) | 75 (65 to 97) | 4.5 (–2 to 11) |
| Hemoglobin, g/dL | 12.8 (11.2 to 14.5) | 12.7 (11.5 to 14.1) | 0.3 (–0.4 to 1.0) |
| White blood cell count, median (IQR), /μL | 5784 (4173 to 8163) | 5480 (4820 to 6830) | –17.5 (–920 to 885) |
| Neutrophils, % | 70.2 (58.6 to 79.9) | 67.8 (62.7 to 76.3) | NA |
| Lymphocytes, % | 19.3 (12.6 to 29.2) | 23.2 (14.9 to 27.4) | NA |
| Macrophages, % | 8.0 (4.3 to 9.2) | 7.6 (6.2 to 8.7) | NA |
| Eosinophils, % | 0.40 (0.15 to 1.28) | 0.65 (0.18 to 1.80) | NA |
| Lymphocyte count, median (IQR), /μL | 1079 (806-1500) | 1299 (899-1608) | –116.5 (–316 to 83) |
| Platelet count, median (IQR), ×103/μL | 207 (168 to 326) | 221 (169 to 327) | –6 (–46 to 34) |
| Glucose, median (IQR), mg/dL | 106 (91 to 126) | 100 (88 to 125) | 2 (–8 to 12) |
| Sodium, median (IQR), mEq/L | 139 (137 to 141) | 138 (136 to 141) | 0.5 (–1 to 2) |
| Potassium, median (IQR), mEq/L | 4.1 (3.8 to 4.5) | 4.0 (3.8 to 4.5) | 0 (–0.2 to 0.2) |
| Estimated GFR, median (IQR), mL/min/1.73m2 | 93 (64 to 118) | 99 (76 to 128) | –11.5 (–28 to 5) |
| Aspartate aminotransferase, median (IQR), U/L | 34 (23 to 52) | 30 (21 to 42) | 4 (–2 to 10) |
| Alanine aminotransferase, median (IQR), U/L | 35 (18 to 49) | 25 (17 to 43) | 4.5 (–3 to 12) |
| Lactate dehydrogenase, median (IQR), U/L | 280 (224 to 405) | 251 (196 to 350) | 30 (–13 to 73) |
| Creatine phosphokinase, median (IQR), U/L | 80 (55 to 133) | 80 (49 to 164) | 0 (–23 to 23) |
| C-reactive protein, median (IQR), mg/dL | 4.0 (1.2 to 9.5) | 3.6 (1.0 to 6.7) | 9.5 (–6 to 25) |
| High-sensitivity cardiac troponin, median (IQR), ng/mL | 0.007 (0.0035 to 0.0185) | 0.008 (0.004 to 0.0123) | 0.0005 (–2.0 to 3.0) |
| D-dimer, median (IQR), μg/ml | 0.60 (0.40 to 1.01) | 0.52 (0.28 to 0.94) | 0.0815 (–0.0082 to 0.0245) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COVID-19, coronavirus disease 2019; D-dimer, dimerized plasma fragment D; GFR, glomerular filtration rate; IQR, interquartile range; NA, not applicable; Pao2, partial pressure of oxygen.
SI conversion factors: To convert alanine aminotransferase, aspartate aminotransferase, creatine phosphokinase, and lactate dehydrogenase to microkatals per liter, multiply by 0.0167; C-reactive protein to milligrams per liter, multiply by 10.0; D-dimer to nanomoles per liter, multiply 5.476; high-sensitivity cardiac troponin to micrograms per liter, multiply by 1.0; glucose to millimoles per liter, multiply by 0.0555; hemoglobin to grams per liter, multiply by 10.0; lymphocyte and white blood cell count to ×109 per liter, multiply by 0.001; platelet count to ×109 per liter, multiply by 1.0; and potassium and sodium to millimoles per liter, multiply by 1.0.